IRIS
PELAIA, CORRADO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.959
AS - Asia 2.665
EU - Europa 1.414
SA - Sud America 939
Continente sconosciuto - Info sul continente non disponibili 248
AF - Africa 94
OC - Oceania 10
Totale 9.329
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.793
SG - Singapore 1.058
IT - Italia 791
BR - Brasile 714
CN - Cina 506
VN - Vietnam 450
IN - India 221
DE - Germania 168
HK - Hong Kong 135
AR - Argentina 90
GB - Regno Unito 86
BD - Bangladesh 81
CA - Canada 80
FI - Finlandia 76
NL - Olanda 50
MX - Messico 46
SE - Svezia 43
EC - Ecuador 42
ID - Indonesia 42
ES - Italia 31
IQ - Iraq 28
RU - Federazione Russa 28
FR - Francia 27
CO - Colombia 25
ZA - Sudafrica 23
VE - Venezuela 21
UA - Ucraina 20
TR - Turchia 17
AT - Austria 16
EG - Egitto 16
PY - Paraguay 16
PL - Polonia 14
PE - Perù 13
JP - Giappone 12
MA - Marocco 12
IE - Irlanda 11
NP - Nepal 11
PK - Pakistan 11
CZ - Repubblica Ceca 10
TW - Taiwan 10
AU - Australia 9
CL - Cile 9
DO - Repubblica Dominicana 9
KE - Kenya 8
MY - Malesia 8
PH - Filippine 8
SA - Arabia Saudita 8
TN - Tunisia 8
UY - Uruguay 8
AE - Emirati Arabi Uniti 7
CR - Costa Rica 7
IL - Israele 7
SC - Seychelles 7
TH - Thailandia 6
UZ - Uzbekistan 6
DZ - Algeria 5
ET - Etiopia 5
JO - Giordania 5
KR - Corea 5
CH - Svizzera 4
EE - Estonia 4
GT - Guatemala 4
IR - Iran 4
LT - Lituania 4
LV - Lettonia 4
PT - Portogallo 4
RO - Romania 4
AL - Albania 3
BE - Belgio 3
BG - Bulgaria 3
HN - Honduras 3
JM - Giamaica 3
KG - Kirghizistan 3
KZ - Kazakistan 3
LB - Libano 3
SI - Slovenia 3
TT - Trinidad e Tobago 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AZ - Azerbaigian 2
BA - Bosnia-Erzegovina 2
CG - Congo 2
GR - Grecia 2
NG - Nigeria 2
OM - Oman 2
PA - Panama 2
SV - El Salvador 2
AW - Aruba 1
BB - Barbados 1
BH - Bahrain 1
BN - Brunei Darussalam 1
BO - Bolivia 1
BS - Bahamas 1
BY - Bielorussia 1
BZ - Belize 1
CI - Costa d'Avorio 1
CY - Cipro 1
EU - Europa 1
GH - Ghana 1
HU - Ungheria 1
KI - Kiribati 1
Totale 9.073
Salva come PNG Salva come JPEG
Città #
San Jose 816
Singapore 402
Dallas 381
Ashburn 363
Santa Clara 221
Ho Chi Minh City 194
Chandler 179
Council Bluffs 178
Bengaluru 164
Hefei 160
Hong Kong 128
Beijing 109
Munich 103
Hanoi 89
Milan 85
Phoenix 82
Chicago 72
Princeton 71
Lawrence 67
São Paulo 65
Los Angeles 57
Turku 52
Catanzaro 48
London 48
Rome 47
Wilmington 42
Boardman 39
Naples 39
New York 38
Haiphong 28
Palermo 28
Florence 23
Orem 23
Helsinki 21
Quito 21
San Francisco 20
Rio de Janeiro 19
Des Moines 18
Mexico City 18
San Nicola Manfredi 18
Bari 16
Brooklyn 16
Thái Bình 16
Amsterdam 15
Biên Hòa 15
Denver 15
Johannesburg 15
Ninh Bình 15
Toronto 15
Baghdad 14
Buenos Aires 13
Guayaquil 13
Montreal 13
Porto Alegre 13
Seattle 13
Warsaw 13
Atlanta 12
Boston 12
Brasília 12
Redwood City 12
Alessandria 11
Belo Horizonte 11
Catania 11
Chennai 11
Troina 11
Curitiba 10
Messina 10
Olomouc 10
Paris 10
Redmond 10
Salvador 10
Tokyo 10
Guarulhos 9
Lima 9
Norwalk 9
Ottawa 9
Buffalo 8
Dublin 8
Galbiate 8
Hải Dương 8
Mascalucia 8
Thái Nguyên 8
Asunción 7
Da Nang 7
Hanover 7
Lamezia Terme 7
Montevideo 7
Mumbai 7
Nairobi 7
Reggio Emilia 7
Taipei 7
The Dalles 7
Ankara 6
Bangkok 6
Bogotá 6
Can Tho 6
Castrovillari 6
Caxias do Sul 6
Cincinnati 6
Columbus 6
Totale 5.181
Salva come PNG Salva come JPEG
Nome #
Patient-derived 3D nasal spheroids reveal epithelial changes following Dupilumab therapy in CRSwNP: a preliminary report 165
25-Hydroxy Vitamin D Detection Using Different Analytic Methods in Patients with Migraine 132
Arg16Gly 132-Adrenoreceptor Polymorphism in Severe Eosinophilic Asthma: Implications for Mepolizumab Long-Term Effectiveness and Clinical Remission 109
An Analytical Method for Assessing Optimal Storage Conditions of Gingival Crevicular Fluid and Disclosing a Peptide Biomarker Signature of Gingivitis by MALDI-TOF MS 107
Benralizumab Effectiveness in Severe Eosinophilic Asthma with and without Chronic Rhinosinusitis with Nasal Polyps: A Real-World Multicenter Study 97
Benralizumab: From the basic mechanism of action to the potential use in the biological therapy of severe eosinophilic asthma 88
Features of severe asthma response to anti-IL5/IL5r therapies: identikit of clinical remission 85
High-flow nasal cannula oxygen therapy for outpatients undergoing flexible bronchoscopy: a randomised controlled trial 85
Biological mechanisms underlying the clinical effects of allergen-specific immunotherapy in asthmatic children 84
Evaluation of a New Interface Combining High-Flow Nasal Cannula and CPAP 82
Type 2 severe asthma: pathophysiology and treatment with biologics 81
Benralizumab in Patients with Severe Eosinophilic Asthma: A Multicentre Real-Life Experience 79
Effects of the first three doses of benralizumab on symptom control, lung function, blood eosinophils, oral corticosteroid intake, and nasal polyps in a patient with severe allergic asthma 79
Uric acid and vascular damage in essential hypertension: Role of insulin resistance 79
Rapid detection and identification of antimicrobial peptide fingerprints of nasal fluid by mesoporous silica particles and MALDI-TOF/TOF mass spectrometry: from the analytical approach to the diagnostic applicability in precision medicine 78
Clinical and Functional Effects of Inhaled Dual Therapy Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease: A Real-Life Study 76
Association Between Sleep Apnea and Valvular Heart Diseases 76
Real-World Evaluation of Dupilumab in the Long-Term Management of Eosinophilic Chronic Rhinosinusitis with Nasal Polyps: A Focus on IL-4 and IL-13 Receptor Blockade 75
Device for Performing Spirometry in Total Laryngectomized Patients 74
New treatments for asthma: From the pathogenic role of prostaglandin D2 to the therapeutic effects of fevipiprant 73
Benefits of secretion clearance with high frequency percussive ventilation in tracheostomized critically ill patients: a pilot study 72
Clinical remission in severe asthma: lights and shadows on an ambitious goal 72
Benralizumab in the treatment of severe asthma: design, development and potential place in therapy 72
Hexagonal Mesoporous Silica as a Rapid, Efficient and Versatile Tool for MALDI-TOF MS Sample Preparation in Clinical Peptidomics Analysis: A Pilot Study. 72
Short term effect of sacubitril/valsartan on comprehensive geriatric assessment in chronic heart failure: a real life analysis 71
Effects of Sacubitril-Valsartan on Clinical, Echocardiographic, and Polygraphic Parameters in Patients Affected by Heart Failure With Reduced Ejection Fraction and Sleep Apnea 71
An integrated metabo-lipidomics profile of induced sputum for the identification of novel biomarkers in the differential diagnosis of asthma and COPD 71
MALDI MS-Based Investigations Targeting SARS-CoV-2 70
Assessment of cephalometric parameters and correlation with the severity of the obstructive sleep apnea syndrome 69
Pathobiology of Type 2 Inflammation in Asthma and Nasal Polyposis 68
Long-Term Clinical and Sustained REMIssion in Severe Eosinophilic Asthma Treated With Mepolizumab: The REMI-M Study 68
Nasal polyposis: Insights in epithelial-mesenchymal transition and differentiation of polyp mesenchymal stem cells 68
Association between right ventricular dysfunction and adverse cardiac events in mild COPD patients 67
Emerging biological treatments for asthma 67
Spotlight on a Short-Time Treatment with the IL-4/IL-13 Receptor Blocker in Patients with CRSwNP: microRNAs Modulations and Preliminary Clinical Evidence 67
Cluster Analysis Identifies Patients With Severe Eosinophilic Asthma Who Achieve Super-Response and Remission With Mepolizumab 66
Basophil activation test for Staphylococcus aureus enterotoxins in severe asthmatic patients 66
Real-life rapidity of benralizumab effects in patients with severe allergic eosinophilic asthma: Assessment of blood eosinophils, symptom control, lung function and oral corticosteroid intake after the first drug dose 65
Current Practice of High Flow through Nasal Cannula in Exacerbated COPD Patients 65
Efficacy and safety of first-line checkpoint inhibitors-based treatments for non-oncogene-addicted non-small-cell lung cancer: a systematic review and meta-analysis 64
Recognizing, quantifying and managing patient-ventilator asynchrony in invasive and noninvasive ventilation. 63
Tissue microRNA dynamics in sinonasal inverted papilloma: implications for pathology and therapy 62
Interleukins 4 and 13 in Asthma: Key Pathophysiologic Cytokines and Druggable Molecular Targets 62
Effect of Statins on Lung Cancer Molecular Pathways: A Possible Therapeutic Role 62
Comparisons of two diaphragm ultrasound-teaching programs: a multicenter randomized controlled educational study. 62
What is the Role of Sex-Related Differences in the Effectiveness and Safety of Biological Drugs used in Patients' Severe Asthma? 61
Imaging of chronic rhinosinusitis with nasal polyps in the era of biological therapies 61
Effect of continuous positive airway pressure on non-fatal stroke and paroxysmal atrial fibrillation recurrence in obstructive sleep apnoea elderly patients 61
Severe Asthma Remissions Induced by Biologics Targeting IL5/IL5r: Results from a Multicenter Real-Life Study 60
Eosinophilic inflammation: An Appealing Target for Pharmacologic Treatments in Severe Asthma 60
Asthma control during COVID-19 lockdown in patients with severe asthma under biological drug treatment 60
Allergy clinics in times of the SARS-CoV-2 pandemic: An integrated model 59
Gingival Crevicular Fluid Peptidome Profiling in Healthy and in Periodontal Diseases. 59
Biologics in severe asthma 59
Switching Biological Therapies in Severe Asthma 58
Nurse led protocols for control of glycaemia in critically ill patients: A systematic review 58
Mapping the SARS-CoV-2–host protein–protein interactome by affinity purification mass spectrometry and proximity-dependent biotin labeling: A rational and straightforward route to discover host-directed anti-SARS-CoV-2 therapeutics 58
Is Bronchiectasis (BE) Properly Investigated in Patients with Severe Asthma? A Real-Life Report from Eight Italian Centers 57
Oxygenation strategies during flexible bronchoscopy: a review of the literature 57
Real-Life Clinical and Functional Effects of Fluticasone Furoate/Umeclidinium/Vilanterol-Combined Triple Therapy in Patients with Chronic Obstructive Pulmonary Disease 57
Patient-ventilator asynchrony in adult critically ill patients 57
Neuron-specific enolase serum levels in COVID-19 are related to the severity of lung injury 57
Clinical and economic consequences of switching from omalizumab to mepolizumab in uncontrolled severe eosinophilic asthma 57
Adherence to omalizumab: A multicenter “real-world” study 57
Effectiveness of Benralizumab in OCS-Dependent Severe Asthma: The Impact of 2 Years of Therapy in a Real-Life Setting 56
Real-Life Effects of Omalizumab on Chronic Rhinosinusitis with Nasal Polyposis 56
Fluid Challenge During Anesthesia: A Systematic Review and Meta-analysis. 56
Oxygen therapy via high flow nasal cannula in severe respiratory failure caused by Sars-Cov-2 infection: a real-life observational study 56
Biological Therapy of Severe Asthma with Dupilumab, a Dual Receptor Antagonist of Interleukins 4 and 13 55
Maxillary sinus mucocele with orbital complications 55
Omalizumab, the first available antibody for biological treatment of severe asthma: more than a decade of real-life effectiveness 55
Therapeutic Role of Tocilizumab in SARS-CoV-2-Induced Cytokine Storm: Rationale and Current Evidence. 55
Switch from omalizumab to benralizumab in allergic patients with severe eosinophilic asthma: A real-life experience from Southern Italy 55
Predictors of renal function worsening in patients with chronic obstructive pulmonary disease (Copd): A multicenter observational study 55
Targeting IL-4 and IL-13 Receptors on Eosinophils in CRSwNP Patients: The Clinical Efficacy of Dupilumab 54
Can Leukotriene Receptor Antagonist Therapy Improve the Control of Patients with Severe Asthma on Biological Therapy and Coexisting Bronchiectasis? A Pilot Study 54
Effects of continuous positive airway pressure on comprehensive geriatric assessment and cognitive function in elderly patients with obstructive sleep apnea syndrome 54
Clinical relevance of understanding mitogen-activated protein kinases involved in asthma 54
Primary mucosal melanoma presenting with a unilateral nasal obstruction of the left inferior turbinate 54
Pre-biologic FeNO might predict anti-IL-5/IL-5Rα response to treatment in severe asthmatics 53
Effects of High-Flow Nasal Cannula on Right Heart Dysfunction in Patients with Acute-on-Chronic Respiratory Failure and Pulmonary Hypertension 53
Are Bronchiectasis (BE) Properly Investigated in Patients with Severe Asthma? A Real-Life Report from 8 Italian Centers 53
New Onset of Eosinophilic Granulomatosis with Polyangiitis Following mRNA-Based COVID-19 Vaccine 52
Real-life effects of benralizumab on allergic chronic rhinosinusitis and nasal polyposis associated with severe asthma 52
Phenotyping severe asthma: a rationale for biologic therapy 52
Interleukin-5 in the Pathophysiology of Severe Asthma 52
Omalizumab lowers asthma exacerbations, oral corticosteroid intake and blood eosinophils: Results of a 5-YEAR single-centre observational study 52
Real-life effectiveness of mepolizumab on forced expiratory flow between 25% and 75% of forced vital capacity in patients with severe eosinophilic asthma 52
Real-life evaluation of the clinical, functional, and hematological effects of mepolizumab in patients with severe eosinophilic asthma: Results of a single-centre observational study 52
Effect of SGLT2-Inhibitors on Polygraphic Parameters in Elderly Patients Affected by Heart Failure, Type 2 Diabetes Mellitus, and Sleep Apnea 51
Switching from omalizumab to mepolizumab: real-life experience from Southern Italy 51
Real-life evaluation of mepolizumab efficacy in patients with severe eosinophilic asthma, according to atopic trait and allergic phenotype 51
Intrinsic laryngeal lipoma treated with transoral Co2 laser microsurgery: An unusual case report 51
Tezepelumab: A potential new biological therapy for severe refractory asthma 51
Effectiveness of benralizumab in severe eosinophilic asthma: Distinct sub-phenotypes of response identified by cluster analysis 51
Extended nitric oxide analysis in patients with chronic rhinosinusitis with nasal polyps, with or without associated asthma 50
Real-life therapeutic effects of beclomethasone dipropionate/formoterol fumarate/glycopyrronium combined triple therapy in patients with chronic obstructive pulmonary disease 50
Association between non-dipping blood pressure pattern and different glucometabolic profile during oral glucose tolerance test 50
Difficult-To-Treat and Severe Asthma: Can Real-World Studies On Effectiveness of Biological Treatments Change the Lives of Patients? 50
Benralizumab: From the Basic Mechanism of Action to the Potential Use in the Biological Therapy of Severe Eosinophilic Asthma 50
Totale 6.502
Salva come PNG Salva come JPEG
Categoria #
all - tutte 69.698
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 69.698
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022199 0 0 0 34 7 8 22 40 29 22 36 1
2022/2023625 141 33 41 25 61 56 26 54 85 30 52 21
2023/2024390 68 46 34 28 13 76 6 18 6 26 24 45
2024/20251.637 169 19 27 34 190 215 109 50 164 52 254 354
2025/20265.119 237 494 773 1.012 465 232 541 245 542 361 118 99
2026/20271.105 81 300 520 204 0 0 0 0 0 0 0 0
Totale 9.329